Gupta V, Kennedy JA, Capo-Chichi J-M, et al. Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL–negative MPN in blast phase. Blood Adv. 2020;4(21):5562-5573.

Registos relacionados

• Gupta V, Kim S, Hu Z-H, et al. Comparison of outcomes of HCT in blast phase of BCR-ABL1(−) MPN with de novo AML and with AML following MDS. Blood Adv. 2020;4(19):4748-4757.
  Publicado em: (2021)
• Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL–negative MPN in blast phase
  Por: Gupta, Vikas, et al.
  Publicado em: (2020)
• Comparison of outcomes of HCT in blast phase of BCR-ABL1(−) MPN with de novo AML and with AML following MDS
  Por: Gupta, Vikas, et al.
  Publicado em: (2020)
• Lee AYY. The changing landscape of anticoagulation in cancer-associated thrombosis. Blood Adv. 2020;4(5):969.
  Publicado em: (2020)
• Shamay M, Kanakry JA, Low JSW, et al. CpG methylation in cell-free Epstein-Barr virus DNA in patients with EBV-Hodgkin lymphoma. Blood Adv. 2020;4(8):1624-1627.
  Publicado em: (2020)